Works by Xue, Shiyin

Results: 2
    1

    Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 14, p. 6195, doi. 10.1002/cam4.2399
    By:
    • Zhu, Feng‐Cai;
    • Hu, Shang‐Ying;
    • Hong, Ying;
    • Hu, Yue‐Mei;
    • Zhang, Xun;
    • Zhang, Yi‐Ju;
    • Pan, Qin‐Jing;
    • Zhang, Wen‐Hua;
    • Zhao, Fang‐Hui;
    • Zhang, Cheng‐Fu;
    • Yang, Xiaoping;
    • Yu, Jia‐Xi;
    • Zhu, Jiahong;
    • Zhu, Yejiang;
    • Chen, Feng;
    • Zhang, Qian;
    • Wang, Hong;
    • Wang, Changrong;
    • Bi, Jun;
    • Xue, Shiyin
    Publication type:
    Article
    2

    Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.

    Published in:
    Cancer Medicine, 2017, v. 6, n. 1, p. 12, doi. 10.1002/cam4.869
    By:
    • Zhu, Feng‐cai;
    • Hu, Shang‐Ying;
    • Hong, Ying;
    • Hu, Yue‐Mei;
    • Zhang, Xun;
    • Zhang, Yi‐Ju;
    • Pan, Qin‐Jing;
    • Zhang, Wen‐Hua;
    • Zhao, Fang‐Hui;
    • Zhang, Cheng‐Fu;
    • Yang, Xiaoping;
    • Yu, Jia‐Xi;
    • Zhu, Jiahong;
    • Zhu, Yejiang;
    • Chen, Feng;
    • Zhang, Qian;
    • Wang, Hong;
    • Wang, Changrong;
    • Bi, Jun;
    • Xue, Shiyin
    Publication type:
    Article